Welcome to our dedicated page for Denali Therapeut news (Ticker: DNLI), a resource for investors and traders seeking the latest updates and insights on Denali Therapeut stock.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a biotechnology and biopharmaceutical company developing product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases, lysosomal storage diseases and other serious conditions. This news page aggregates company-reported updates, press releases and related market announcements about Denali’s programs and corporate activities.
Readers can find coverage of Denali’s investigational enzyme replacement therapy tividenofusp alfa (DNL310) for Hunter syndrome (MPS II), including milestones related to its Biologics License Application, Priority Review status and the ongoing Phase 2/3 COMPASS study. News items also describe clinical and regulatory progress for other TransportVehicle™-enabled programs such as DNL126 (ETV:SGSH) for Sanfilippo syndrome type A, DNL952 (ETV:GAA) for Pompe disease, and TV-enabled antibody and oligonucleotide programs for Alzheimer’s and Parkinson’s disease.
In addition to pipeline updates, Denali’s releases discuss collaborations with partners such as Biogen, Takeda and Sanofi, a royalty funding agreement with Royalty Pharma tied to future net sales of tividenofusp alfa, and financial results reflecting research and development spending and launch preparations. Corporate governance and leadership changes, board appointments and participation in healthcare and investor conferences are also reported.
Investors and followers of DNLI can use this page to review historical and recent announcements on clinical trial progress, regulatory interactions, financing transactions and strategic partnerships as disclosed by the company in its public communications.
Denali Therapeutics Inc. announced the completion of enrollment for Regimen G in the Phase 2/3 HEALEY ALS Platform Trial, evaluating their eIF2B agonist DNL343. The trial is a collaboration between the Sean M. Healey & AMG Center and the Northeast ALS Consortium. The completion of enrollment marks a significant milestone in the development of DNL343 for the treatment of ALS, with positive feedback from investigators and leaders in the field.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.